

ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON

ROOM: ROSSETTI ROOM

SATURDAY MAY 4TH, 2024 8:00 AM – 09:00 AM

CO-CHAIRS : DR ELENA ELIMOVA, DR GAIL DARLING & DR AAMER MAHMUD
 SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To identify clinical trial research opportunities in malignancies of the colon within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to malignancies of the colon.
- To integrate and apply new clinical trial methodologies in malignancies of the colon in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators.

8:00 am	Welcome	
8:05 am	GA.4: A Randomized Phase II Study of Paclitaxel and Ramucriumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma	Dr E Elimova
8:20 am	ES.3 (NEEDS): Neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma versus definitive chemoradiotherapy with salvage surgery as needed.	Dr R Wong & Dr J Lukovic
8:35 am	TORO: Toronto Resection of Oligomets Trial	Dr E Wakeam & Dr G Darling
8:45 am	NCTN Esophagogastric Task Force Update	Dr E Elimova & Dr A Mahmud
8:50 am	A Randomized Blinded Study of Durvalumab and Chemotherapy vs Chemotherapy and Placebo in Patients with Carcinoma of Unknown Primary	Dr J Monzon & Dr M Vickers
9:00 am	Meeting Adjourned	

